• - Rivastigmin-Pflaster 9,5 Rivastigmin-Kapsel12 Placebo
• - mg/24 h mg/d
• -ITT-LOCF Population n = 251 n = 256 n = 282
• -ADAS-Cog (n=248) (n=253) (n=281)
• -Mittlere Baseline ± 27.0 ±10.3 27.9 ± 9.4 28.6 ± 9.9
• + Rivastigmin-Pflaster 9,5 Rivastigmin-Kapsel Placebo
• + mg/24 h 12 mg/d
• +ITT-LOCF Population n = 251 n = 256 n = 282
• +ADAS-Cog (n=248) (n=253) (n=281)
• +Mittlere Baseline ± 27.0 ±10.3 27.9 ± 9.4 28.6 ± 9.9
• -Mittlere Änderung in -0.6 ± 6.4 -0.6 ± 6.2 1.0 ± 6.8
• -Woche 24 ± SD
• -p-Wert versus Placebo 0.005*1 0.003*1
• -ADCS-CGIC (n=248) (n=253) (n=278)
• -Mittlerer Wert ± SD 3.9 ± 1.20 3.9 ± 1.25 4.2 ± 1.26
• -p-Wert versus Placebo 0.010*2 0.009*2
• -ADCS-ADL (n=247) (n=254) (n=281)
• -Mittlere Baseline ± SD 50.1 ± 16.3 49.3 ± 15.8 49.2 ± 16.0
• -Mittlere Änderung in -0.1 ± 9.1 -0.5 ± 9.5 -2.3 ± 9.4
• -Woche 24 ± SD
• -p-Wert versus Placebo 0.013*1 0.039*1
• +Mittlere Änderung in Woche -0.6 ± 6.4 -0.6 ± 6.2 1.0 ± 6.8
• +24 ± SD
• +p-Wert versus Placebo 0.005*1 0.003*1
• +ADCS-CGIC (n=248) (n=253) (n=278)
• +Mittlerer Wert ± SD 3.9 ± 1.20 3.9 ± 1.25 4.2 ± 1.26
• +p-Wert versus Placebo 0.010*2 0.009*2
• +ADCS-ADL (n=247) (n=254) (n=281)
• +Mittlere Baseline ± SD 50.1 ± 16.3 49.3 ± 15.8 49.2 ± 16.0
• +Mittlere Änderung in Woche -0.1 ± 9.1 -0.5 ± 9.5 -2.3 ± 9.4
• +24 ± SD
• +p-Wert versus Placebo 0.013*1 0.039*1